エクスペリクス監督は、彼女の株の29%を売却し、彼女の賭け額を約1億6600万ドルに削減した。 Exelixis director sells nearly 29% of her shares, reducing her stake to about $1.06 million.

癌治療の開発に重点を置くバイオテクノロジー企業エクセリクシスは,その取締役であるメアリー・C・ベッカールが2月14日に12,210株を売却し,その株式を28.65%削減した. Exelixis, a biotech company focused on developing cancer treatments, saw its director Mary C. Beckerle sell 12,210 shares on February 14, reducing her stake by 28.65%. 平均価格 34.88 ドルで売却され,彼女の保有額は約 106 万ドルに減少した. The sale, at an average price of $34.88, brought her total holdings down to about $1.06 million. Exelixisの市場キャピタルは982億ドルで 平均的なアナリストの目標価格は37.24ドルです Exelixis has a market cap of $9.82 billion and an average analyst target price of $37.24. 最近,いくつかの機関投資家が保有額を調整し,一部は持有額を大幅に増やしました. Several institutional investors have recently adjusted their holdings, with some increasing their stakes significantly.